Jenny Davies is a Principal Associate in the Intellectual Property team. Her Masters in Molecular and Cellular Biochemistry from Oxford University and wealth of experience across the Life Sciences and Medical Device sector have facilitated her roles as Lead Associate in ground-breaking patent litigation up to the UK Court of Appeal, and assisting with billion dollar pharmaceutical deals.
Jenny provides strategic advice to help clients protect and exploit their R&D investment in the Life Sciences sector. Jenny's background in Biochemistry enables her to build strong working relationships with her clients and to better understand their key drivers and the commercial and technical challenges they face.
A highlight of Jenny's contentious portfolio is her work on biological therapies. Jenny acted for the Kennedy Trust for Rheumatology Research in the first dispute involving biological therapies in the UK, and is currently the lead Associate on the Fujifilm Kyowa Kirin Biologics v AbbVie case, in which Fujifilm sought a novel type of declaratory relief to clear the way for a pharmaceutical launch in a market worth over $16 billion globally and over £400m in the UK alone. In the first instance judgment given on 3 March 2017, for the first time the UK courts granted declaratory relief to a company seeking to launch a product in the face of a myriad of pending patent applications.
Jenny assisted in defending H. Lundbeck in a leading case involving its blockbuster anti-depressant enantiomer drug, Escitalopram. The case itself was highly complex involving substantial organic chemistry experiments in the evidence. Earlier in her career, she successfully defended two patent infringement claims for Brightwake Limited (Advancis Medical) in relation to wound care products (in the Patents County Court (now IPEC) and the High Court). Jenny has also worked on cases involving gene patents, inhalable and injectable products and opiod pharmaceuticals.
Jenny's non-contentious experience is also extensive. Jenny has completed high-value high-value licensing and collaboration deals in the Life Sciences sector, including a deal for AstraZeneca worth over a billion dollars. In her transactional work, Jenny has been described as "instrumental" and a client was "deeply impressed by the work Jenny did… Jenny showed an unusual capacity to think creatively and constructively… She also has a very commercial mindset…Jenny is also a very dedicated professional and her attention to detail and devotion to the task at hand is indeed impressive."
In 2014, Jenny was seconded to the Gowling WLG China office as Interim Chief Representative Officer. Her work on the ground in China enabled her to develop a wealth of experience in this important jurisdiction. Jenny acted for the Guangzhou office's largest client, with over 100 infringement matters to date. Her work in China was assisted by a previous client secondment, and her experience managing the client's global patent and design infringements.